Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-24. (Canceled)

25. (Currently Amended) An encapsulated product comprising discrete, solid particles having a substantially uniform shape and a diameter of up to about 10 mm, wherein each particle comprises:

an encapsulant dispersed throughout a plasticized mass comprising starch which is not neither substantially destructured or nor substantially dextrinized, and at least one component for controlling the rate of release of the encapsulant,

wherein said encapsulant is at least one pharmaceutical component, neutraceutical component, nutritional component, fragrance component, or biologically active component,

wherein said plasticized mass comprises about 40% or more by weight of at least one matrix material, based on the weight of the final product, and at least one plasticizer comprising water,

wherein the encapsulant and plasticized matrix material form an at least substantially homogeneous mixture, and

wherein the amount of said encapsulant is from about 1% by weight to about 85% by weight, based upon the weight of the matrix material.

26. (Currently Amended) An encapsulated product according to claim 25 wherein said plasticized matrix material comprises a partially gelatinized starch, which starch is not neither substantially destructured or nor substantially destrinized.

27. (Currently Amended) An encapsulated product comprising discrete, solid particles having a substantially uniform shape and a diameter of up to about 10 mm, wherein each particle comprises:

an encapsulant dispersed throughout a plasticized mass comprising starch which is not neither substantially destructured or nor substantially dextrinized, and at least one component for controlling the rate of release of the encapsulant,

wherein said encapsulant is at least one pharmaceutical component, neutraceutical component, nutritional component, fragrance component, or biologically active component,

wherein said plasticized mass comprises about 40% or more by weight of at least one matrix material, based on the weight of the final product, and at least one plasticizer,

wherein the encapsulant and plasticized matrix material form an at least substantially homogeneous mixture,

wherein the amount of said encapsulant is from about 1% by weight to about 85% by weight, based upon the weight of the matrix material, and

wherein said encapsulant is coated with a film-forming material prior to dispersion within said plasticized mass.

- 28. (Original) An encapsulated product according to claim 25 wherein said particles are in the form of a tablet, or a pellet.
- 29. (Original) An encapsulated product according to claim 28 wherein said particles are coated with a film-forming material.
- 30. (Original) An encapsulated product according to claim 25 wherein said at least one release-rate controlling component is a hydrophobic component.

31. (Original) An encapsulated product according to claim 30 wherein said hydrophobic component is at least one member selected from the group consisting of fats, oils, waxes, fatty acids, emulsifiers, polyolefins, paraffin, polyvinyl acetate and derivatives thereof, and modified starches.

32-33. (Canceled)

- 34. (Original) An encapsulated product according to claim 25 which has a specific density of from about 800 g/liter to about 1500 g/liter.
- 35. (Previously Presented) An encapsulated product according to claim 25 wherein the length-to-diameter ratio of said particles is from about 0.1 to about 10.

36. (Canceled)

- 37. (Original) An encapsulated product according to claim 25 wherein said particles have a substantially non-expanded, substantially non-cellular structure.
- 38. (Original) An encapsulated product according to claim 25 wherein said encapsulant is released in an aqueous or gastric juice environment in an amount of no more than from about 10% in about 1 hour to no less than about 90% in about 24 hours.
- 39. (Previously Presented) An encapsulated product according to claim 25 wherein: the amount of the matrix material is from about 60% by weight to about 95% by weight, based upon the weight of the final product, and

Bernhard van Lengerich

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

the amount of said at least one component used to control the rate of release of the

encapsulant is from about 5% by weight to about 50% by weight, based upon the weight of

the matrix material.

40. (Original) An encapsulated product according to claim 39 wherein said particles

have a diameter of from about 0.5 mm to about 5 mm and a length-to-diameter ratio of

about 0.5 to about 2.

41. (Canceled)

42. (Original) An encapsulated product according to claim 25 wherein said

plasticized matrix comprises durum wheat or semolina.

43-45. (Canceled)

46. (Previously Presented) An encapsulated product according to claim 25 wherein

said encapsulant is at least one member selected from the group consisting of antioxidants,

phytochemicals, hormones, microorganisms, prebiotics, probiotics, enzymes, formulations

containing zidovudine, macromolecular polypeptides, aromatic nitro and nitroso compounds

and their metabolites useful as anti-viral and anti-tumor agents, HIV protease inhibitors,

antibiotics, viruses, steroids, oligopeptides, dipeptides, amino acids, fragrance components,

adenosine derivatives, sulfated tannins, monoclonal antibodies, and metal complexes of

water-soluble texathyrin.

47-49. (Canceled)

{P32853 01597004.DOCX}

50. (Previously Presented) An encapsulated product according to claim 25 wherein said plasticized matrix material further comprises at least one member selected from the group consisting of cyclodextrins, dextrins, monosaccharides, disaccharides, polyvinylpyrrolidone, copolymers of N-vinylpyrrolidone and vinyl acetate, polyvinyl alcohol, cellulose esters, cellulose ethers, and polyethylene glycol.

51. (Canceled)

52. (Currently Amended) An encapsulated product comprising:

discrete, solid particles having a substantially uniform shape wherein each particle comprises:

a plasticized matrix material in an amount of about 40% or more by weight, based on the weight of the final encapsulated product, wherein said plasticized matrix material comprises starch which is not neither substantially destructured or nor substantially destructured.

an encapsulant dispersed throughout the plasticized matrix material, and at least one component for controlling the rate of release of the encapsulant, wherein said encapsulant comprises at least one pharmaceutical component, neutraceutical component, nutritional component, fragrance component, or biologically active component,

wherein said matrix material comprises at least one member selected from the group consisting of durum wheat, semolina, wheat flour, wheat gluten, soy protein, hydrocolloids, casein, and gelatin, and at least one plasticizer comprising water,

wherein the encapsulant and plasticized matrix material form an at least substantially homogeneous mixture, and

wherein the amount of said encapsulant is from about 1% by weight to about 85% by weight, based upon the weight of the matrix material.

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

53. (Currently Amended) An encapsulated product according to claim 52 wherein said plasticized matrix material comprises a partially gelatinized starch, which starch is not neither substantially destructurized or nor substantially destruized.

54. (Currently Amended) An encapsulated product comprising:

discrete, solid particles having a substantially uniform shape wherein each particle comprises:

a plasticized matrix material in an amount of about 40% or more by weight, based on the weight of the final encapsulated product, wherein said plasticized matrix material comprises starch which is not neither substantially destructurized or nor substantially destructurized.

an encapsulant dispersed throughout the plasticized matrix material, and at least one component for controlling the rate of release of the encapsulant, wherein said encapsulant comprises at least one pharmaceutical component, neutraceutical component, nutritional component, fragrance component, or biologically active component,

wherein said matrix material comprises at least one member selected from the group consisting of durum wheat, semolina, wheat flour, wheat gluten, soy protein, hydrocolloids, casein, and gelatin, and at least one plasticizer,

wherein the encapsulant and plasticized matrix material form an at least substantially homogeneous mixture,

wherein the amount of said encapsulant is from about 1% by weight to about 85% by weight, based upon the weight of the matrix material, and

wherein said encapsulant is coated with a film-forming material prior to dispersion within said plasticized mass.

Bernhard van Lengerich

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

55. (Original) An encapsulated product according to claim 52 wherein said particles

are in the form of a tablet, or a pellet.

56. (Original) An encapsulated product according to claim 52 wherein said particles

are spherical.

57. (Original) An encapsulated product according to claim 55 wherein said particles

are coated with a film-forming material.

58. (Original) An encapsulated product according to claim 52 wherein said at least

one release-rate controlling component is a hydrophobic component.

59. (Original) An encapsulated product according to claim 58 wherein said

hydrophobic component is at least one member selected from the group consisting of fats,

oils, waxes, fatty acids, emulsifiers, polyolefins, paraffin, polyvinyl acetate and derivatives

thereof, and modified starches.

60. (Canceled)

61. (Original) An encapsulated product according to claim 52 which has a specific

density of from about 800 g/liter to about 1500 g/liter.

62. (Previously Presented) An encapsulated product according to claim 52 wherein

the length-to-diameter of said particles is from about 0.1 to about 10.

63. (Canceled)

{P32853 01597004.DOCX}

Bernhard van Lengerich

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

64. (Original) An encapsulated product according to claim 52 wherein said particles

have a substantially non-expanded, substantially non-cellular structure.

65. (Original) An encapsulated product according to claim 52 wherein said

encapsulant is released in an aqueous or gastric juice environment in an amount of no more

than from about 10% in about 1 hour to no less than about 90% in about 24 hours.

66. (Original) An encapsulated product according to claim 52 wherein the amount

of said at least one component for controlling the rate of release of the encapsulant is up to

about 70% by weight, based on the weight of the matrix material.

67. (Original) An encapsulated product according to claim 52 wherein said particles

have a diameter of from about 0.5 mm to about 5 mm and a length-to-diameter ratio of

about 0.5 to about 2.

68. (Canceled)

69. (Original) An encapsulated product according to claim 52 wherein said matrix

material comprises at least one member selected from the group consisting of durum wheat,

semolina, wheat flour, wheat gluten, and soy protein.

70. (Original) An encapsulated product according to claim 52 wherein said matrix

material comprises at least one member selected from the group consisting of durum wheat

and semolina.

71-72. (Canceled)

{P32853 01597004.DOCX}

73. (Original) An encapsulated product according to claim 52 wherein said discrete, solid particles have a diameter of up to about 10 mm.

74. (Canceled)

75. (Previously presented) An encapsulated product according to claim 52 wherein said encapsulant is at least one member selected from the group consisting of antioxidants, phytochemicals, hormones, microorganisms, prebiotics, probiotics, enzymes, formulations containing zidovudine, macromolecular polypeptides, aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents, HIV protease inhibitors, antibiotics, viruses, steroids, oligopeptides, dipeptides, amino acids, fragrance components, adenosine derivatives, sulfated tannins, monoclonal antibodies, and metal complexes of water-soluble texathyrin.

76-78. (Canceled)

79. (Previously Presented) An encapsulated product according to claim 52 wherein said plasticized matrix material further comprises at least one member selected from the group consisting of cyclodextrins, dextrins, monosaccharides, disaccharides, polyvinylpyrrolidone, copolymers of N-vinylpyrrolidone and vinyl acetate, polyvinyl alcohol, cellulose esters, cellulose ethers, and polyethylene glycol.

80. (Canceled)

81. (Previously presented) An encapsulated product according to claim 52 wherein: the amount of the matrix material is from about 60% by weight to about 95% by weight, based upon the weight of the final product, and

Bernhard van Lengerich

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

the amount of said at least one component used to control the rate of release of the encapsulant is from about 5% by weight to about 50% by weight, based upon the weight of the matrix material.

- 82. (Original) An encapsulated product according to claim 52 wherein said encapsulant comprises at least one member selected from the group consisting of enzymes and microorganisms.
- 83. (Currently Amended) An encapsulated product comprising discrete, solid particles having a substantially uniform shape wherein each particle comprises:

an encapsulant dispersed throughout a plasticized matrix material comprising starch which is not neither substantially destructurized or nor substantially destruized, said matrix material comprising at least one member selected from the group consisting of durum wheat, semolina, vital wheat gluten, soy protein, hydrocolloids, casein, and gelatin, and at least one plasticizer comprising water,

wherein said encapsulant comprises at least one pharmaceutical component, neutraceutical component, nutritional component, fragrance component, or biologically active component,

wherein the encapsulant and plasticized matrix material form an at least substantially homogeneous mixture,

wherein the amount of said encapsulant is from about 3% by weight to about 50% by weight, based upon the weight of the matrix material, and

wherein the amount of said matrix material is about 40% or more by weight, based upon the weight of the final encapsulated product.

84. (Original) An encapsulated product according to claim 83 wherein said matrix material comprises semolina or durum wheat.

85. (Original) An encapsulated product according to claim 83 wherein said encapsulant comprises at least one member selected from the group consisting of enzymes and microorganisms.

86-90. (Canceled)

- 91. (Previously Presented) An encapsulated product according to claim 25, comprising about 3% by weight to about 50% by weight of the encapsulant, based upon the weight of the matrix material.
- 92. (Previously Presented) An encapsulated product according to claim 25, comprising about 5% by weight to about 20% by weight of the encapsulant, based upon the weight of the matrix material.
- 93. (Previously Presented) An encapsulated product according to claim 25, wherein the encapsulant is in liquid form.
- 94. (Withdrawn) An encapsulated product according to claim 25, wherein the encapsulant is in solid form.
- 95. (Previously Presented) An encapsulated product according to claim 52, comprising about 3% by weight to about 50% by weight of the encapsulant, based upon the weight of the matrix material.

96. (Previously Presented) An encapsulated product according to claim 52, comprising about 5% by weight to about 20% by weight of the encapsulant, based upon the weight of the matrix material.

97. (Previously Presented) An encapsulated product according to claim 83, comprising about 5% by weight to about 20% by weight of the encapsulant, based upon the weight of the matrix material.

98-100. (Canceled)

101. (Previously Presented) An encapsulated product according to Claim 25 wherein said plasticized mass comprises from about 60% by weight to about 95% by weight of at least one matrix material.

102. (Canceled)

103. (Previously Presented) An encapsulated product according to Claim 52 comprising from about 60% by weight to about 95% by weight of the matrix material, based upon the weight of the final encapsulated product.

104. (Canceled)

105. (Previously Presented) An encapsulated product according to Claim 83 comprising from about 60% by weight to about 95% by weight of the matrix material, based upon the weight of the final encapsulated product.

106-107. (Canceled)

Bernhard van Lengerich

AMENDMENT UNDER 37 C.F.R. 1.111

Attorney Docket No. BVL-102A

108. (Previously Presented) An encapsulated product according to claim 25 wherein

said matrix material comprises at least one member selected from the group consisting of

durum wheat, semolina, wheat flour, wheat gluten, native or modified starches, soy protein,

casein, and gelatin.

109. (Previously Presented) An encapsulated product according to claim 25 wherein

said matrix material comprises at least one member selected from the group consisting of

durum wheat, semolina, wheat flour, wheat gluten, native starches and modified starches.

110. (Previously Presented) An encapsulated product according to claim 27 wherein

said matrix material comprises at least one member selected from the group consisting of

durum wheat and semolina.

111. (Previously Presented) An encapsulated product according to claim 25 wherein

at least a portion of the starch is not cooked.

112. (Previously Presented) An encapsulated product according to claim 25 wherein

the starch is not cooked or is cooked so that the specific energy input during cooking is

below about 100 Wh/kg.

{P32853 01597004.DOCX}